Brevan Howard Capital Management’s Amedisys AMED Stock Holding History

Brevan Howard Capital Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6,954	Closed	-$644K	–	1829
2025 Q1	$644K	Buy	6,954 +4,318	+164%	+$398K	0.01%	655
2024 Q4	$239K	Buy	+2,636	New	+$242K	﹤0.01%	852
2024 Q1	–	Sell	-3,228	Closed	-$307K	–	991
2023 Q4	$307K	Buy	+3,228	New	+$302K	﹤0.01%	706

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Brevan Howard Capital Management's AMED Position: Q2 2025 in Review

Brevan Howard Capital Management sold out of Amedisys (AMED) in Q2 2025, closing a stake of 6,954 shares — an estimated $644K sold.

Brevan Howard Capital Management first reported a position in AMED in Q4 2023 and held it in 3 quarters. The position peaked at $644K in Q1 2025. 319 funds tracked by Wall St. Rank hold AMED as of Q2 2025.

Brevan Howard Capital Management reported no remaining Amedisys position as of Q2 2025 after selling out during the quarter.
Brevan Howard Capital Management sold 6,954 Amedisys shares in Q2 2025, an estimated $644K.
Brevan Howard Capital Management first reported a position in Amedisys in Q4 2023 and held it in 3 quarters.
Brevan Howard Capital Management's Amedisys position peaked at $644K in Q1 2025.
319 funds tracked by Wall St. Rank held Amedisys as of Q2 2025.

Based on Brevan Howard Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.